Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 4Ovarian Neoplasms 2Lymphoma 2Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 9Cyclophosphamide 6fludarabine phosphate 4aldesleukin 3Radiotherapy 3Gemcitabine 3Drug Therapy 3Docetaxel 3Cetuximab 3temsirolimus 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2fludarabine 2entinostat 2durvalumab 2belinostat 2atezolizumab 2Sirolimus 2Paclitaxel 2Methods 2Metformin 2Irinotecan 2Interferon-alpha 2Bortezomib 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1tremelimumab 1tocilizumab 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × valspodar × Breast × Clear all
NCT00001302 2008-03-04

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
80 enrolled
BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Kidney Neoplasms, Lymphoma, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡